NASDAQ · ELUT
Healthcare · Biotechnology
$0.86
Up+$0.04 (+5.17%)
Updated Aug 14, 2026, 4:14 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ELUT closed at $0.86 after 21 trading sessions, down 9.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $0.81 | $0.8693 | $0.7642 | $0.8603 | 122.5K |
| Aug 12, 2026 | $0.8156 | $0.8626 | $0.78 | $0.818 | 14.26K |
| Aug 11, 2026 | $0.8679 | $0.87 | $0.7779 | $0.8015 | 30.4K |
| Aug 10, 2026 | $0.866 | $0.8999 | $0.814 | $0.814 | 30.84K |
| Aug 7, 2026 | $0.876 | $0.8934 | $0.85 | $0.85 | 22.46K |
| Aug 6, 2026 | $0.86 | $0.8944 | $0.86 | $0.881 | 13.06K |
| Aug 5, 2026 | $0.8735 | $0.899 | $0.8242 | $0.872 | 39.07K |
| Aug 4, 2026 | $0.8689 | $0.8893 | $0.85 | $0.872 | 28.07K |
| Aug 3, 2026 | $0.85 | $0.8902 | $0.8255 | $0.8669 | 41.73K |
| Jul 31, 2026 | $0.89 | $0.91 | $0.81 | $0.8568 | 160.34K |
| Jul 30, 2026 | $0.88 | $0.9278 | $0.88 | $0.905 | 69.57K |
| Jul 29, 2026 | $0.90 | $0.9253 | $0.8722 | $0.88 | 28.06K |
| Jul 28, 2026 | $0.93 | $0.937 | $0.90 | $0.915 | 23.62K |
| Jul 27, 2026 | $0.969 | $0.9907 | $0.904 | $0.9604 | 21.67K |
| Jul 24, 2026 | $0.9541 | $1.00 | $0.9001 | $0.93 | 67.75K |
| Jul 23, 2026 | $0.9001 | $0.9581 | $0.90 | $0.9325 | 50.22K |
| Jul 22, 2026 | $0.9405 | $0.95 | $0.9103 | $0.932 | 87.43K |
| Jul 21, 2026 | $0.93 | $0.961 | $0.9201 | $0.95 | 49.77K |
| Jul 20, 2026 | $0.9434 | $0.95 | $0.9215 | $0.9301 | 26.37K |
| Jul 17, 2026 | $0.96 | $0.98 | $0.88 | $0.95 | 251.44K |
| Jul 16, 2026 | $0.96 | $1.00 | $0.95 | $0.95 | 831.93K |
The latest Smart Investors Daily articles mentioning ELUT.
ELUT research
Company profile and research snapshot.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2025 | Lake Street | Buy | — |
| May 9, 2025 | Lake Street | Buy | — |
| Mar 7, 2025 | Cantor Fitzgerald | Overweight | — |
| Nov 15, 2024 | Cantor Fitzgerald | Overweight | — |
| Sep 6, 2024 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 13, 2026
On Thursday, Elutia (NASDAQ:ELUT) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to
Benzinga · Aug 13, 2026
Funded through launch: secured up to $26 million of capital without an equity offeringThe unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection riskThe demand is strong: 96% of
Benzinga · Aug 13, 2026
Elutia (NASDAQ:ELUT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 34.62 percent increase over losses of $(0.26) per share from the
Benzinga · Jul 17, 2026
Elutia (NASDAQ:ELUT) sells SimpliDerm to Cellution Biologics for up to $11M to boost its balance sheet ahead of the NXT-41x launch.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ELUT.
